Patents by Inventor Mario Otto
Mario Otto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124925Abstract: A method for assessing the status of degradation and/or integrity of one or more nucleic acids in a sample, which includes amplifying at least two overlapping regions within at least one locus and detecting the amount of the amplification products using at least two probes, where one probe binds to an overlapping region and the other probe binds to a non-overlapping region. Also, a method of designing primers and/or probes for amplifying at least two overlapping regions within at least one single copy locus or multicopy locus. Also a primer and a primer pair for amplifying at least two overlapping regions from one nucleic acid template which is a multicopy locus present in loci in the human genome. Also a kit including primers and/or probes for assessing the status of degradation and/or integrity of one or more nucleic acids in a sample.Type: ApplicationFiled: September 15, 2023Publication date: April 18, 2024Inventors: Miroslav VRANES, Ralf PEIST, Mario SCHERER, Stefan Otto CORNELIUS
-
Publication number: 20240084363Abstract: Oligonucleotide primers and probes for quantifying and/or detecting human male DNA in a forensic sample. The oligonucleotides are useful for amplifying a multicopy locus within the human Y-chromosome (MCL-Y) that shares at least 80% sequence identity to a sequence according to SEQ ID NO. 3 over a stretch of at least 60 base pairs. The oligonucleotides hybridize under stringent conditions to a nucleic acid having at least one sequence selected from the group consisting of SEQ ID NO. 3 to SEQ ID NO. 11 and/or SEQ ID NO. 17 to SEQ ID NO. 25. Kits including the oligonucleotide primers, probes and/or primer pairs and reagents for performing an amplification reaction on DNA recovered from a forensic sample are also disclosed.Type: ApplicationFiled: October 6, 2023Publication date: March 14, 2024Inventors: Miroslav VRANES, Ralf PEIST, Mario SCHERER, Stefan Otto CORNELIUS, Margaretha KÖNIG
-
Publication number: 20240066156Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: ApplicationFiled: June 30, 2023Publication date: February 29, 2024Inventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Patent number: 11730834Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: GrantFiled: June 29, 2020Date of Patent: August 22, 2023Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Publication number: 20220008442Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+(CH3)3. The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.Type: ApplicationFiled: September 21, 2021Publication date: January 13, 2022Inventors: Mario Otto, Dana C. Baiu, Bryan P. Bednarz, Jamey Paul Weichert
-
Patent number: 11147823Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+(CH3)3. The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.Type: GrantFiled: July 12, 2017Date of Patent: October 19, 2021Assignee: Wisconsin Alumni Research FoundationInventors: Mario Otto, Dana C. Baiu, Bryan P. Bednarz, Jamey Paul Weichert
-
Publication number: 20200330567Abstract: A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula: wherein R1 is a radioactive halogen isotope, n is 18 and R2 is —N+(CH3)3.Type: ApplicationFiled: July 2, 2020Publication date: October 22, 2020Inventors: Jamey Weichert, Paul M. Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz
-
Publication number: 20200330621Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: ApplicationFiled: June 29, 2020Publication date: October 22, 2020Inventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Patent number: 10751430Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: GrantFiled: July 25, 2017Date of Patent: August 25, 2020Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Patent number: 10736949Abstract: A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula: wherein R1 is a radioactive halogen isotope, n is 18 and R2 is —N+(CH3)3.Type: GrantFiled: July 18, 2017Date of Patent: August 11, 2020Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Paul M. Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz
-
Patent number: 9925283Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+H3, —N+H2X, —N+HX2, or —N+HX3, wherein each X is independently —CH3 or —C2H5. The compounds can be used to treat multiple myeloma or to detect multiple myeloma. In therapeutic treatment, R1 includes a radionuclide that locally delivers therapeutic dosages of radiation to the multiple myeloma tumors cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radiolabel.Type: GrantFiled: April 11, 2016Date of Patent: March 27, 2018Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Paul Weichert, Chorom Pak, Benjamin Titz, Fotis Asimakopoulos, Roberta Marino, Mario Otto, Kevin R. Kozak
-
Publication number: 20180021461Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.Type: ApplicationFiled: July 25, 2017Publication date: January 25, 2018Inventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
-
Publication number: 20180015154Abstract: A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula: wherein R1 is a radioactive halogen isotope, n is 18 and R2 is —N+(CH3)3.Type: ApplicationFiled: July 18, 2017Publication date: January 18, 2018Inventors: Jamey Weichert, Paul M. Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz
-
Publication number: 20180015113Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+(CH3)3. The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.Type: ApplicationFiled: July 12, 2017Publication date: January 18, 2018Inventors: Mario Otto, Dana C. Baiu, Bryan P. Bednarz, Jamey Paul Weichert
-
Publication number: 20160296646Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+H3, —N+H2X, —N+HX2, or —N+HX3, wherein each X is independently —CH3 or —C2H5. The compounds can be used to treat multiple myeloma or to detect multiple myeloma. In therapeutic treatment, R1 includes a radionuclide that locally delivers therapeutic dosages of radiation to the multiple myeloma tumors cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radiolabel.Type: ApplicationFiled: April 11, 2016Publication date: October 13, 2016Inventors: Jamey Paul Weichert, Chorom Pak, Benjamin Titz, Fotis Asimakopoulos, Roberta Marino, Mario Otto, Kevin R. Kozak